<PAPER>
  <mode2 name="19240040_arathi" hasDoc="yes" version="1258"/>
  <TITLE>
    <s sid="1">Suppression of Humoral Immunity by Perfluorooctanoic Acid is Independent of Elevated Serum Corticosterone Concentration in Mice <CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp1" novelty="None" advantage="None"/></s>
  </TITLE>
  <ABSTRACT>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-1">
      <s sid="2">The T-cell&#8211;dependent antibody response is suppressed in mice exposed to 3.75, 7.5, 15, and 30 mg PFOA (perfluorooctanoic acid)/kg body weight (bw).<CoreSc1 atype="GSC" type="Res" conceptID="Res1" novelty="None" advantage="None"/></s>
      <s sid="3">Reduced bw accompanied immunosuppression at 15 and 30 mg/kg.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs1" novelty="None" advantage="None"/></s>
      <s sid="4">We investigated the hypothesis that the observed immunosuppression is secondary to elevated serum corticosterone levels by assessing immune function in adrenalectomized (adx) or sham-operated C57BL/6N female mice exposed to 0, 7.5, or 15 mg PFOA/kg bw in drinking water for 10 days.<CoreSc1 atype="GSC" type="Hyp" conceptID="Hyp2" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Obj" conceptID="Obj1" novelty="None" advantage="None"/></s>
      <s sid="5">Bw, primary antibody responses to a T-dependent antigen, clinical serum chemistries related to liver health, and serum corticosterone levels were evaluated.<CoreSc1 atype="GSC" type="Met" conceptID="Met1" novelty="None" advantage="None"/></s>
      <s sid="6">Exposure to 15 mg/kg decreased bw by approximately 10% after 8 days of dosing and until 2 days postdosing in both adx and sham animals; bw of adx animals were still reduced 5 days postdosing.<CoreSc1 atype="GSC" type="Res" conceptID="Res2" novelty="None" advantage="None"/></s>
      <s sid="7">IgM antibody titers were statistically reduced by 15% in sham animals and 18% in adx animals exposed to 15 mg/kg and by 11.8% in adx animals exposed to 7.5 mg/kg.<CoreSc1 atype="GSC" type="Res" conceptID="Res3" novelty="None" advantage="None"/></s>
      <s sid="8">Corticosterone concentrations were elevated by 157% in dosed sham animals relative to control animals and were reduced by 27% in dosed adx animals relative to control animals (neither changes were statistically significant).<CoreSc1 atype="GSC" type="Res" conceptID="Res4" novelty="None" advantage="None"/></s>
      <s sid="9">Clinical serum chemistries related to liver health were not statistically altered by either dose or adrenalectomy.<CoreSc1 atype="GSC" type="Res" conceptID="Res5" novelty="None" advantage="None"/></s>
      <s sid="10">The failure of adrenalectomy to protect mice from the immunosuppressive effects of PFOA indicates that suppression of antibody synthesis is not the result of liver toxicity or stress-related corticosterone production.<CoreSc1 atype="GSC" type="Con" conceptID="Con1" novelty="None" advantage="None"/></s>
    </p>
  </ABSTRACT>
  <BODY>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-2">
      <s sid="11">Perfluoroalkyl acids (PFAAs) are fluorinated compounds used to manufacture myriad consumer products, from adhesives and fire retardant surfaces to nonstick coatings and lubricants.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac1" novelty="None" advantage="None"/></s>
      <s sid="12">PFAAs undergo chemical, microbial, and photolytic degradation to a limited number of extremely stable degradation products, including perfluorooctanoic acid (PFOA).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac2" novelty="None" advantage="None"/></s>
      <s sid="13">PFOA is also a polymerization aid used in the manufacture of fluorinated polymers and elastomers.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj2" novelty="None" advantage="None"/></s>
      <s sid="14">As a result of its use and as a degradation product of other PFAAs, PFOA is widespread in environmental media and has been reported in the serum and tissues of humans and wildlife (<xref class="xref-bibr" href="#ref-5" rid="xref-ref-5-1">Lau et al., 2007</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac3" novelty="None" advantage="None"/></s>
      <s sid="15">Concerns about PFOA's toxicological effects prompted a preliminary risk assessment by the U.S. Environmental Protection Agency (EPA) and, although relatively few studies have evaluated PFOA's immunomodulatory potential, immunotoxicity was cited as an endpoint of concern in a review of the risk assessment by the EPA Science Advisory Board.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac4" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-3">
      <s sid="16">The studies cited in the preliminary risk assessment reported reductions in lymphoid organ weights and suppression of de novo antibody synthesis (<xref class="xref-bibr" href="#ref-20" rid="xref-ref-20-1">Yang et al., 2000</xref>, <xref class="xref-bibr" href="#ref-21" rid="xref-ref-21-1">2001</xref>, <xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-1">2002</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac5" novelty="None" advantage="None"/></s>
      <s sid="17">In these initial studies and in subsequent studies (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-1">DeWitt et al., 2008</xref>; <xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-1">Loveless et al., 2008</xref>), oral exposure to 30 mg PFOA/kg body weight (bw) reduced antigen-specific IgM antibody synthesis in mice.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac6" novelty="None" advantage="None"/></s>
      <s sid="18">We previously reported that the serum concentration associated with this dose was 1.6 &#215; 10<sup>5</sup> ng/ml after 15 days of exposure.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac7" novelty="None" advantage="None"/></s>
      <s sid="19">The lowest observed adverse effect level for alteration of primary (IgM) antibody titers was 3.75 mg/kg, with a serum concentration of 7.4 &#215; 10<sup>4</sup> ng/ml, which is approximately 150 times greater than concentrations in highly exposed human populations (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-2">DeWitt et al., 2008</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac8" novelty="None" advantage="None"/></s>
      <s sid="20">In a previous study (unpublished data) the adrenal glands of female C57BL/6 mice exposed to 30 mg/kg PFOA via gavage for 10 or 15 days were enlarged relative to controls.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac9" novelty="None" advantage="None"/></s>
      <s sid="21">Histopathological analysis revealed increased cytoplasmic vacuolization in the zona fasciculata, the region of the adrenal primarily responsible for glucocorticoid production.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac10" novelty="None" advantage="None"/></s>
      <s sid="22">Exposure to 30 mg/kg was also associated with reductions in bw and increases in liver weight.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac11" novelty="None" advantage="None"/></s>
      <s sid="23">Therefore, overt toxicity and stress rather than a direct effect of PFOA on immune responses were considered as potential modulating factors of immune suppression at this dose.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac12" novelty="None" advantage="None"/></s>
      <s sid="24">In addition, a recently published paper suggested that alterations in lymphoid organs and IgM synthesis in mice exposed to PFOA were the result of severe overt toxicity and stress and that the immune system was not a specific target (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-2">Loveless et al., 2008</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac13" novelty="None" advantage="None"/></s>
    </p>
    <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-4">
      <s sid="25">To address the potential role of elevated corticosterone production in the suite of effects previously reported (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-3">DeWitt et al., 2008</xref>), we evaluated lymphoid organ weights, T-cell&#8211;dependent antibody responses, clinical serum chemistry parameters related to liver health, and serum corticosterone concentrations in sham-operated or adrenalectomized (adx) C57BL/6 mice exposed to 3.75, 7.5, or 15 mg/kg of PFOA.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa1" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Exp" conceptID="Exp1" novelty="None" advantage="None"/></s>
      <s sid="26">Our objectives were to determine the influence of corticosterone on PFOA-induced immune suppression and to examine markers of liver toxicity associated with PFOA-induced changes to immune function.<CoreSc1 atype="GSC" type="Goa" conceptID="Goa2" novelty="None" advantage="None"/></s>
    </p>
    <SEC>
      <TITLE>MATERIALS AND METHODS</TITLE>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Animals.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-5">
        <s sid="27">C57BL/6N female mice (6&#8211;7 weeks of age) were purchased from Charles River Laboratories (Raleigh, NC).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp2" novelty="None" advantage="None"/></s>
        <s sid="28">Half of the mice were adx, and half received sham adrenalectomy operations (sham); surgeries were performed at Charles River Laboratories prior to arrival at the U.S. EPA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp3" novelty="None" advantage="None"/></s>
        <s sid="29">Once at the U.S. EPA's animal facilities (accredited by the Association for Assessment and Accreditation of Laboratory Animal Care), animals were housed in groups of six in polycarbonate cages with hardwood chip bedding (Beta chip; Northeaster Products, Warrensburg, NY).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp4" novelty="None" advantage="None"/></s>
        <s sid="30">They were provided a 12-h light:dark cycle (light, 0600&#8211;1800 h; dark, 1800&#8211;0600 h), maintained at 22.3 &#177; 1.1&#176;C and 50 &#177; 10% humidity, and given ad libitum access to both food (5P00 Prolab RMH 3000; PMI Nutrition International, Richmond, IN) and water.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp5" novelty="None" advantage="None"/></s>
        <s sid="31">Animals were acclimated for 1 day before dosing began.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp6" novelty="None" advantage="None"/></s>
        <s sid="32">All procedures employed in this study were approved in advance by the Institutional Animal Care and Use Committee of the National Health and Environmental Effects Research Laboratory, U.S. EPA.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp7" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Dosing solutions.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-6">
        <s sid="33">PFOA was purchased from Fluka Chemical (Steinheim, Switzerland) as its ammonium salt (&#8805; 98% purity, lot 421207/1 319030).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp8" novelty="None" advantage="None"/></s>
        <s sid="34">PFOA drinking water dosing solutions were prepared based on total compound weight, as described by <xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-4">DeWitt et al. (2008)</xref> at concentrations of 100, 50, or 25 mg/l (to provide doses of 15, 7.5, or 3.75 mg/kg/day, respectively, based on average daily water consumption and animal bw).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp9" novelty="None" advantage="None"/></s>
        <s sid="35">Dosing water for adx mice was supplemented with 1% sodium chloride to ameliorate sodium deficiency induced by adrenalectomy.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp10" novelty="None" advantage="None"/></s>
        <s sid="36">Mice received PFOA-containing drinking water for 10 consecutive days.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp11" novelty="None" advantage="None"/></s>
        <s sid="37">Dosing water was changed and water consumption per cage (based on water bottle weights) was recorded twice weekly.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp12" novelty="None" advantage="None"/></s>
        <s sid="38">Vehicle controls received deionized water (sham) or deionized water supplemented with 1% sodium chloride (adx) for 10 days.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp13" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Experimental design.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-7">
        <s sid="39">Animals arrived in two separate groups; one group was used for clinical chemistry analysis of serum and the other group was used for measurement of corticosterone and antigen-specific IgM antibody titers.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp14" novelty="None" advantage="None"/></s>
        <s sid="40">Animals used for clinical serum chemistries were not immunized.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp15" novelty="None" advantage="None"/></s>
        <s sid="41">Each endpoint (clinical serum chemistry, corticosterone, IgM) group contained five to seven animals.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp16" novelty="None" advantage="None"/></s>
        <s sid="42">Bw were recorded just prior to dosing, bi-weekly during the dosing period, and just prior to sacrifice.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp17" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-8">
        <s sid="43">Serum from animals for clinical chemistries was collected after 5 or 10 days of exposure.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp18" novelty="None" advantage="None"/></s>
        <s sid="44">Animals were euthanized in a stratified order (one animal from 0 mg/kg, one animal from 3.75 mg/kg, etc.), anesthetized with carbon dioxide and exsanguinated by neck vein transection.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp19" novelty="None" advantage="None"/></s>
        <s sid="45">Blood was collected and held at room temperature for 30 min and centrifuged at 4&#176;C to separate serum, which was then frozen at &#8722;80&#176;C until analysis.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp20" novelty="None" advantage="None"/></s>
        <s sid="46">Serum from animals for corticosterone was collected immediately prior to the start of dosing, after 10 days of exposure, and 5 days after exposure ended; the latter group of animals was also immunized and serum was used for IgM evaluation.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp21" novelty="None" advantage="None"/></s>
        <s sid="47">On the days of blood collection, movement in and out of the animal suite was limited.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp22" novelty="None" advantage="None"/></s>
        <s sid="48">Animals were euthanized by dose group to minimize disturbances to other groups and blood was collected from all animals/cage via neck vein transection within three minutes of removal from the animal suite.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp23" novelty="None" advantage="None"/></s>
        <s sid="49">Blood was processed as described above for later analysis of corticosterone.<CoreSc1 atype="GSC" type="Met" conceptID="Met2" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Clinical chemistries.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-9">
        <s sid="50">Serum was thawed and analyzed for levels of the following, using a Konelab 30 clinical chemistry analyzer (Thermo Clinical Labsystems, Espoo, Finland) based on relevant standards for: alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), total cholesterol (CHOL), creatinine (CREA), gamma glutamyl transferase (GGT), glucose (GLUC), lactate dehydrogenase (LDH), sorbitol dehydrogenase (SDH), total protein (PROT), and triglycerides (TRIG).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp24" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Corticosterone.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-10">
        <s sid="51">Corticosterone levels were measured by radioimmunoassay (Coat-A-Count Rat Corticosterone Kit, Siemens Medical Solutions Diagnostics, Los Angeles, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp25" novelty="None" advantage="None"/></s>
        <s sid="52">Assay limit of detection (LOD) was 5.7 ng/ml.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp26" novelty="None" advantage="None"/></s>
        <s sid="53">Two replicates per sample were run if more than 100 &#956;l of serum had been collected; otherwise only one replicate was run.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp27" novelty="None" advantage="None"/></s>
        <s sid="54">Values less than the LOD were recorded as 5.7 ng/ml.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp28" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">IgM antibody titers.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-11">
        <s sid="55">Animals were immunized on the day after PFOA exposure ended by intravenous injection of 4.0 &#215; 10<sup>7</sup> sheep red blood cells (SRBCs) in 0.2 ml of sterile saline.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp29" novelty="None" advantage="None"/></s>
        <s sid="56">Five days later, animals were euthanized in a stratified order (one animal from 0 mg/kg, one animal from 3.75 mg/kg, etc.), by carbon dioxide inhalation and exsanguinated by neck vein transection.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp30" novelty="None" advantage="None"/></s>
        <s sid="57">Blood was processed as described above for later analysis of SRBC-specific IgM antibodies.<CoreSc1 atype="GSC" type="Met" conceptID="Met3" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-12">
        <s sid="58">IgM titers were determined as described previously (<xref class="xref-bibr" href="#ref-1" rid="xref-ref-1-1">DeWitt et al., 2005</xref>).<CoreSc1 atype="GSC" type="Met" conceptID="Met4" novelty="None" advantage="None"/></s>
        <s sid="59">Briefly, flatbottom 96-well Immunolon-2 ELISA microtiter plates (Dynatech Labs, Chantilly, VA) were coated with 125 &#956;l of 2 &#956;g/ml of SRBC membrane (1.46 mg/ml stock solution diluted in phosphate-buffered saline [PBS], prepared according to <xref class="xref-bibr" href="#ref-18" rid="xref-ref-18-1">Temple et al., 1995</xref>) and then incubated at 4&#176;C for at least 16 h.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp31" novelty="None" advantage="None"/></s>
        <s sid="60">Each plate included 20 wells coated with pooled serum collected from healthy mice 5 days after primary immunization with SRBCs, and 16 wells contained 100 &#956;l of PBS as blanks.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp32" novelty="None" advantage="None"/></s>
        <s sid="61">After washing, blocking of nonspecific binding, and addition of serum samples (serially diluted from 1:8 to 1:4096), secondary antibody (goat anti-mouse IgM horseradish peroxidase; Accurate Chemical and Scientific Corp., Westbury, NY) was added.<CoreSc1 atype="GSC" type="Exp" conceptID="Exp33" novelty="None" advantage="None"/></s>
        <s sid="62">Following three washes and addition of substrate (one tablet of 2,2&#8217;-azino-di-(3-ethylbenzthiazoline) sulfonic acid, 10 mg) (ABTS; Sigma Chemical Company, St Louis, MO) added to 50 ml of phosphate-citrate buffer with one tablet of urea hydroxide peroxide (Sigma) in 100 ml of distilled water, 0.05M final solution], plates were incubated for 45 min at room temperature and then read at 410 nm on a SpectraMax 350 plate reader (Molecular Devices, Sunnyvale, CA).<CoreSc1 atype="GSC" type="Exp" conceptID="Exp34" novelty="None" advantage="None"/></s>
      </p>
      <h5 xmlns:xhtml="http://www.w3.org/1999/xhtml">Statistical analysis.</h5>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-13">
        <s sid="63">All data are presented as mean &#177; SEM.<CoreSc1 atype="GSC" type="Met" conceptID="Met5" novelty="None" advantage="None"/></s>
        <s sid="64">Statistical analyses were performed with the SAS System (SAS Institute, Cary, NC).<CoreSc1 atype="GSC" type="Met" conceptID="Met6" novelty="None" advantage="None"/></s>
        <s sid="65">We performed a one-way repeated measures ANOVA on bw by dose within sham and adx groups and a two-way ANOVA for each measurement variable (antibody titers, corticosterone concentration, and clinical serum chemistries), with dose and operation (adx vs. sham) as independent variables.<CoreSc1 atype="GSC" type="Met" conceptID="Met7" novelty="None" advantage="None"/></s>
        <s sid="66">When ANOVA indicated a statistically significant dose effect within operation, we made individual post hoc comparisons using Tukey's test and a t-test.<CoreSc1 atype="GSC" type="Met" conceptID="Met8" novelty="None" advantage="None"/></s>
        <s sid="67">Statistical significance was determined using an &#945; of 0.05.<CoreSc1 atype="GSC" type="Met" conceptID="Met9" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>RESULTS</TITLE>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Bw and Water Consumption</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-14">
        <s sid="68">Only bw of animals used for measurement of IgM antibody titers are presented.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs2" novelty="None" advantage="None"/></s>
        <s sid="69">Bw of sham animals (<xref class="xref-fig" href="#F1" rid="xref-fig-1-1">Fig. 1A</xref>) dosed with 15 mg/kg PFOA were 7.6% lower than bw of control animals at the eighth day of dosing and 9.8% lower 2 days postdosing (p &lt; 0.05).<CoreSc1 atype="GSC" type="Res" conceptID="Res6" novelty="None" advantage="None"/></s>
        <s sid="70">Bw of adx animals (<xref class="xref-fig" href="#F1" rid="xref-fig-1-2">Fig. 1B</xref>) dosed with 15 mg/kg PFOA were 9.6% lower, on average, from the eighth day of dosing until 5 days postdosing, compared with control animals (p &lt; 0.05).<CoreSc1 atype="GSC" type="Res" conceptID="Res7" novelty="None" advantage="None"/></s>
        <s sid="71">In addition, bw of adx animals dosed with 7.5 mg/kg PFOA were 10.3% lower than bw of control animals two days postdosing (p &lt; 0.05).<CoreSc1 atype="GSC" type="Res" conceptID="Res8" novelty="None" advantage="None"/></s>
        <s sid="72">Water consumption did not vary by dose (data not shown).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs3" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Clinical Serum Chemistries</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-16">
        <s sid="73">Triglyceride level was the only clinical serum chemistry parameter that demonstrated a statistically significant dose-dependency (<xref class="xref-table" href="#T1" rid="xref-table-wrap-1-1">Tables 1</xref> and <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-1">2</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res9" novelty="None" advantage="None"/></s>
        <s sid="74">Triglyceride levels in sham animals dosed with 3.75, 7.5, or 15 mg/kg PFOA for 5 days were 44.8, 57.8, and 61.2% lower, respectively, than levels measured in sham control animals.<CoreSc1 atype="GSC" type="Res" conceptID="Res10" novelty="None" advantage="None"/></s>
        <s sid="75">In adx animals only the 7.5 and 15 mg/kg groups were statistically lower than the adx control animals (59.9 and 75.2%, respectively).<CoreSc1 atype="GSC" type="Res" conceptID="Res11" novelty="None" advantage="None"/></s>
        <s sid="76">On average, triglyceride levels were lower after ten days of exposure compared with five days of exposure, but the differences between triglyceride levels after five or ten days of exposure were not statistically significant.<CoreSc1 atype="GSC" type="Res" conceptID="Res12" novelty="None" advantage="None"/></s>
        <s sid="77">A few other clinical chemistry parameters were statistically elevated or decreased relative to control responses, but no changes indicated a trend associated with dose, duration of exposure, or adrenalectomy (<xref class="xref-table" href="#T1" rid="xref-table-wrap-1-2">Tables 1</xref> and <xref class="xref-table" href="#T2" rid="xref-table-wrap-2-2">2</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res13" novelty="None" advantage="None"/></s>
        <s sid="78">In general, clinical serum chemistry parameters of dosed animals did not differ statistically from those of control animals.<CoreSc1 atype="GSC" type="Res" conceptID="Res14" novelty="None" advantage="None"/></s>
      </p>
      <h4 xmlns:xhtml="http://www.w3.org/1999/xhtml">Corticosterone and IgM Antibody Titers</h4>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-21">
        <s sid="79">Baseline corticosterone levels in serum collected prior to dosing were 125.6 &#177; 59.0 ng/ml for the sham animals and 5.7 &#177; 0 ng/ml for the adx animals (all adx animals were below LOD).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs4" novelty="None" advantage="None"/></s>
        <s sid="80">After 10 days of PFOA dosing, average corticosterone concentrations in sham animals were approximately 157% greater in dosed animals compared with control animals (<xref class="xref-fig" href="#F2" rid="xref-fig-2-1">Fig. 2A</xref>; only the 15 mg/kg group was statistically different from controls).<CoreSc1 atype="GSC" type="Res" conceptID="Res15" novelty="None" advantage="None"/></s>
        <s sid="81">Five days after dosing ended, average corticosterone levels in sham animals were 73% greater in dosed animals compared with control animals (<xref class="xref-fig" href="#F2" rid="xref-fig-2-2">Fig. 2A</xref>; no groups statistically different from controls).<CoreSc1 atype="GSC" type="Res" conceptID="Res16" novelty="None" advantage="None"/></s>
        <s sid="82">Average corticosterone concentrations in adx animals were 27% lower in dosed animals compared with control animals after 10 days of PFOA dosing (<xref class="xref-fig" href="#F2" rid="xref-fig-2-3">Fig. 2B</xref>; no groups statistically different from controls) and within 10% of each other 5 days after dosing ended (<xref class="xref-fig" href="#F2" rid="xref-fig-2-4">Fig. 2B</xref>).<CoreSc1 atype="GSC" type="Res" conceptID="Res17" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-23">
        <s sid="83">Dosing with 15 mg/kg PFOA for 10 days reduced SRBC-specific IgM antibody titers (<xref class="xref-fig" href="#F3" rid="xref-fig-3-1">Fig. 3</xref>) by 18% relative to controls in sham animals and by 15.4% in adx animals (p &lt; 0.05).<CoreSc1 atype="GSC" type="Res" conceptID="Res18" novelty="None" advantage="None"/></s>
        <s sid="84">Dosing with 7.5 mg/kg PFOA also reduced IgM antibody titers by 11.8% relative to controls in adx animals (p &lt; 0.05).<CoreSc1 atype="GSC" type="Res" conceptID="Res19" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>DISCUSSION</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-25">
        <s sid="85">The data presented here indicate that suppression of T-cell&#8211;dependent antibody responses (TDAR) in PFOA-treated mice is independent of increased serum corticosterone levels and liver toxicity as measured by clinical serum chemistries.<CoreSc1 atype="GSC" type="Con" conceptID="Con2" novelty="None" advantage="None"/></s>
        <s sid="86">In this study, we evaluated clinical serum chemistry parameters related to liver health, serum corticosterone levels, and TDAR in sham-operated or adx adult C57BL/6N female mice dosed with one of several concentrations of PFOA for ten days to verify corticosterone levels or changes to clinical serum chemistries as factors in suppression of IgM TDAR.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj3" novelty="None" advantage="None"/></s>
        <s sid="87">None of the clinical serum chemistry parameters measured indicated a gross alteration in liver health of animals in the study.<CoreSc1 atype="GSC" type="Res" conceptID="Res20" novelty="None" advantage="None"/></s>
        <s sid="88">Dosing with 15 mg/kg of PFOA statistically reduced IgM antibody titers in both sham and adx animals and 7.5 mg/kg PFOA also reduced titers in adx animals.<CoreSc1 atype="GSC" type="Res" conceptID="Res21" novelty="None" advantage="None"/></s>
        <s sid="89">In addition, serum corticosterone levels were elevated in dosed animals relative to control animals in the sham group.<CoreSc1 atype="GSC" type="Res" conceptID="Res22" novelty="None" advantage="None"/></s>
        <s sid="90">As expected, relatively low levels of corticosterone were measured in the adx animals (16.0&#8211;51.9 ng/ml range).<CoreSc1 atype="GSC" type="Obs" conceptID="Obs5" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-26">
        <s sid="91"><xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-2">Yang et al. (2002)</xref> evaluated the effects of PFOA on antigen-specific antibody responses and lymphocyte proliferation in response to T- or B-cell mitogens in male C57BL/6 mice fed a diet of 30 mg PFOA/kg for 15 days.<CoreSc1 atype="GSC" type="Met" conceptID="Met10" novelty="None" advantage="None"/></s>
        <s sid="92">Antigen-specific IgM and IgG serum titers were suppressed relative to responses of unexposed animals.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac14" novelty="None" advantage="None"/></s>
        <s sid="93">In a set of studies designed to corroborate the immune alterations reported by <xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-3">Yang et al. (2002)</xref>, we previously reported (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-5">DeWitt et al., 2008</xref>) suppression of IgM antibody titers in female C57BL/6 given 3.75, 7.5, 15, and 30 mg/kg of PFOA in drinking water.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac15" novelty="None" advantage="None"/></s>
        <s sid="94">At the two lower doses, no effects on lymphoid organ weights or bw were observed.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac16" novelty="None" advantage="None"/></s>
        <s sid="95">However, at the 15 and 30 mg/kg doses, bw and lymphoid organ weights were reduced, and at the 30 mg/kg dose (in a previous study, unpublished), cytoplasmic vacuolization in the zona fasciculata of the adrenal was increased, suggesting the potential for stress-induced immune suppression from increased corticosterone production.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac17" novelty="None" advantage="None"/></s>
        <s sid="96">In addition, <xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-3">Loveless et al. (2008)</xref> reported suppression of IgM antibody titers in male CD-1 mice exposed to 10 or 30 mg/kg PFOA for 28 days, confirming our results and the results of <xref class="xref-bibr" href="#ref-19" rid="xref-ref-19-4">Yang et al. (2002)</xref> in another strain of mice.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac18" novelty="None" advantage="None"/></s>
        <s sid="97">However, <xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-4">Loveless et al. (2008)</xref> asserted that these immune findings represented secondary responses to systemic toxicity and stress as indicated by bw loss and elevated serum corticosterone levels.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac19" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-27">
        <s sid="98">Corticosterone is a glucocorticoid that increases in response to many stressors.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj4" novelty="None" advantage="None"/></s>
        <s sid="99">Elevated production of corticosterone is immunosuppressive, although duration of exposure to elevated levels is critical in determining the outcome.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac20" novelty="None" advantage="None"/></s>
        <s sid="100">The relationship between increased corticosterone concentration and changes in immune function has been represented by the area under the curve (AUC) for serum corticosterone (<xref class="xref-bibr" href="#ref-10" rid="xref-ref-10-1">Pruett, 2001</xref>, <xref class="xref-bibr" href="#ref-11" rid="xref-ref-11-1">2003</xref>; <xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-1">Pruett and Fan, 2001</xref>; <xref class="xref-bibr" href="#ref-12" rid="xref-ref-12-1">Pruett et al., 1999</xref>, <xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-1">2003</xref>, 2007).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac21" novelty="None" advantage="None"/></s>
        <s sid="101">The cumulative effects of hormones on downstream functions are often evaluated by calculating the AUC, which can be thought of as total hormonal output over a given time period (<xref class="xref-bibr" href="#ref-9" rid="xref-ref-9-1">Pruessner et al., 2003</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac22" novelty="None" advantage="None"/></s>
        <s sid="102">The AUC concept for corticosterone illustrates the linear relationship between the duration of corticosterone elevation and suppression of certain immune parameters.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac23" novelty="None" advantage="None"/></s>
        <s sid="103">Circulating leukocytes, lymphoid organ weights, and changes to lymphoid organ histopathology occur at AUCs between 1380 and 4188 ng/ml/h (<xref class="xref-bibr" href="#ref-15" rid="xref-ref-15-1">Pruett and H&#233;bert, 2007</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac24" novelty="None" advantage="None"/></s>
        <s sid="104">However, antibody production, the response that we evaluated, is relatively insensitive to increases in corticosterone; <xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-2">Pruett and Fan (2001)</xref> reported that SRBC-specific IgG antibodies in mice were only suppressed at AUCs greater than 3000 ng/ml/h, and enhanced at lower AUCs.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac25" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-28">
        <s sid="105">In the current study corticosterone was only evaluated at three time points separated by days, rather than hours, so we were not able to calculate the AUC for corticosterone.<CoreSc1 atype="GSC" type="Met" conceptID="Met11" novelty="None" advantage="None"/></s>
        <s sid="106">However, we did measure serum corticosterone immediately after animals had experienced handling (restrained), injection (immunized with SRBCs), and chemical exposure (dosed with PFOA for 10 days).<CoreSc1 atype="GSC" type="Met" conceptID="Met12" novelty="None" advantage="None"/></s>
        <s sid="107">The highest corticosterone concentration that we measured in any mouse was 380 ng/ml.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs6" novelty="None" advantage="None"/></s>
        <s sid="108">In comparison, in a study of the effects of atrazine and ethanol on stress responses in mice, peak corticosterone concentrations were 1200 and 800 ng/ml, respectively (<xref class="xref-bibr" href="#ref-14" rid="xref-ref-14-2">Pruett et al., 2003</xref>), which were two to four times the peak corticosterone levels measured in our study.<CoreSc1 atype="GSC" type="Res" conceptID="Res23" novelty="None" advantage="None"/><CoreSc2 atype="GSC" type="Bac" conceptID="Bac26" novelty="None" advantage="None"/></s>
        <s sid="109"><xref class="xref-bibr" href="#ref-13" rid="xref-ref-13-3">Pruett and Fan (2001)</xref> reported that an AUC greater than 3000 ng/ml/h was necessary to reduce IgG antibody titers and <xref class="xref-bibr" href="#ref-7" rid="xref-ref-7-1">Neigh et al. (2004)</xref> reported that an AUC of approximately 250 ng/ml/h was necessary to reduce IgM antibody titers.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac27" novelty="None" advantage="None"/></s>
        <s sid="110">Given that the average corticosterone concentrations for all of our groups were less than 200 ng/ml, it is unlikely that we achieved an AUC sufficient to reduce IgM antibody titers in our study.<CoreSc1 atype="GSC" type="Res" conceptID="Res24" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-29">
        <s sid="111">Serum corticosterone levels associated with suppression of IgM antibody titers in CD-1 mice exposed to 30 mg/kg PFOA for 28 days were between 400 and 500 ng/ml, which were more than 200% greater than levels in control animals (<xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-5">Loveless et al., 2008</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac28" novelty="None" advantage="None"/></s>
        <s sid="112"><xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-1">Fang et al. (2008)</xref> reported increases in cortisol, changes in lymphocyte populations, and alteration in cytokines in BALB/c mice exposed to 3 or 5 mg/kg perfluorononanoic acid via gavage for 14 days.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac29" novelty="None" advantage="None"/></s>
        <s sid="113">Increases in cortisol in exposed animals were approximately 50% greater relative to control animals, but concentrations were all lower than 100 ng/ml.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac30" novelty="None" advantage="None"/></s>
        <s sid="114">In both of these studies, the authors suggested that the immunomodulatory effects observed were from activation of the HPA axis by the chemical under study.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac31" novelty="None" advantage="None"/></s>
        <s sid="115"><xref class="xref-bibr" href="#ref-6" rid="xref-ref-6-6">Loveless et al. (2008)</xref> suggested that the immune suppression was the result of a stress response and <xref class="xref-bibr" href="#ref-3" rid="xref-ref-3-2">Fang et al. (2008)</xref> suggested that the observed changes in immune parameters were associated with increases in cortisol levels.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac32" novelty="None" advantage="None"/></s>
        <s sid="116">Our data contradict these assertions and indicate that immunosuppression is independent of elevated corticosterone.<CoreSc1 atype="GSC" type="Con" conceptID="Con3" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-30">
        <s sid="117">PFOA ligates the peroxisome proliferator&#8211;activated receptor alpha (PPAR-&#945;), a ligand-activated transcription factor that regulates gene expression related to lipid and glucose homeostasis, cell proliferation and differentiation, and inflammation.<CoreSc1 atype="GSC" type="Obj" conceptID="Obj5" novelty="None" advantage="None"/></s>
        <s sid="118">PPAR-&#945; agonists, including PFOA, have been reported to reduce inflammation induced by carageenan (<xref class="xref-bibr" href="#ref-16" rid="xref-ref-16-1">Taylor et al., 2002</xref>, <xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-1">2005</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac33" novelty="None" advantage="None"/></s>
        <s sid="119">When coadministered with RU-486, a glucocorticoid receptor (GR) partial agonist, the anti-inflammatory effect of PFOA was not altered, indicating that GR receptors do not mediate the effects of PFOA (<xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-2">Taylor et al., 2005</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac34" novelty="None" advantage="None"/></s>
        <s sid="120"><xref class="xref-bibr" href="#ref-17" rid="xref-ref-17-3">Taylor et al. (2005)</xref> therefore suggested that a mechanism mediated by endogenous corticosterone release following activation of the HPA axis was not sufficient to explain PFOA's anti-inflammatory effects.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac35" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-31">
        <s sid="121">Although the involvement of the HPA axis at higher doses of fluorinated compounds is possible, it is not sufficient to explain immune suppression at lower doses or at doses where signs of generalized toxicity (i.e., loss in bw or decreased bw gain) are not evident.<CoreSc1 atype="GSC" type="Con" conceptID="Con4" novelty="None" advantage="None"/></s>
        <s sid="122">Although we do not discount that overt toxicity is likely at higher doses (i.e., 15 and 30 mg/kg PFOA), where loss of bw, even when adjusted for increases in liver weight, also occurred, a stress response is insufficient to explain immune suppression at 7.5 mg/kg PFOA in the adx animals.<CoreSc1 atype="GSC" type="Con" conceptID="Con5" novelty="None" advantage="None"/></s>
        <s sid="123">The lack of dose-dependent changes to clinical serum chemistries also indicates that liver toxicity, as a symptom of overt toxicity, was not induced by PFOA exposure or adrenalectomy at lower doses.<CoreSc1 atype="GSC" type="Con" conceptID="Con6" novelty="None" advantage="None"/></s>
        <s sid="124">As glucocorticoids autoregulate GR expression, we are evaluating GR levels in livers of mice exposed to PFOA.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot1" novelty="None" advantage="None"/></s>
        <s sid="125">Changes in GR levels would be an indicator of PFOA-induced increases in corticosterone during the exposure period.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac36" novelty="None" advantage="None"/></s>
        <s sid="126">However, changes in GR levels would not explain the reductions in antibody synthesis we observed in the adx animals.<CoreSc1 atype="GSC" type="Con" conceptID="Con7" novelty="None" advantage="None"/></s>
      </p>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-32">
        <s sid="127">In our previous study, female C57BL/6N mice exposed to 3.75 or 7.5 mg/kg PFOA for 15 days had suppressed IgM antibody titers but no changes in body, spleen, or thymus weights (<xref class="xref-bibr" href="#ref-2" rid="xref-ref-2-6">DeWitt et al., 2008</xref>).<CoreSc1 atype="GSC" type="Bac" conceptID="Bac37" novelty="None" advantage="None"/></s>
        <s sid="128">In the current study, suppression of IgM antibody titers was observed in both sham and adx animals exposed to PFOA for 10 days.<CoreSc1 atype="GSC" type="Obs" conceptID="Obs7" novelty="None" advantage="None"/></s>
        <s sid="129">Although these doses were associated with about 10% weight loss in the adx animals relative to controls (even after bw was adjusted for increases in liver weights), the absence of significant changes to clinical serum chemistries and low levels of corticosterone indicate that our immune findings do not represent secondary responses to systemic toxicity and stress.<CoreSc1 atype="GSC" type="Res" conceptID="Res25" novelty="None" advantage="None"/></s>
        <s sid="130"><xref class="xref-bibr" href="#ref-8" rid="xref-ref-8-1">Peden-Adams et al. (2008)</xref> observed suppression of both T-cell&#8211;dependent (SRBC-specific) and T-cell&#8211;independent (trinitrophenyl-specific) antibody synthesis in mice exposed to perfluorooctane sulfonate for 28 days.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac38" novelty="None" advantage="None"/></s>
        <s sid="131">No changes in bw, lymphoid organ weights, or lymphoid cell populations were observed at the lower doses associated with immune suppression.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac39" novelty="None" advantage="None"/></s>
        <s sid="132">Although they did not measure corticosterone, Peden-Adams et al. (2008) hypothesized that alterations in B cells or antigen presenting cells were associated with the reduced antibody responses.<CoreSc1 atype="GSC" type="Bac" conceptID="Bac40" novelty="None" advantage="None"/></s>
        <s sid="133">We are also evaluating PFOA's ability to affect responses to T-cell&#8211;independent antigens.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot2" novelty="None" advantage="None"/></s>
        <s sid="134">In addition, we are consulting with the epidemiologists studying PFOA-exposed humans in West Virginia to determine if titers to immunizations have been affected by PFOA.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot3" novelty="None" advantage="None"/></s>
        <s sid="135">Results of such studies will help to direct future immunotoxicity studies with PFOA and other PPAR-&#945; ligands.<CoreSc1 atype="GSC" type="Mot" conceptID="Mot4" novelty="None" advantage="None"/></s>
        <s sid="136">As human PPAR-&#945; expression is only one-tenth that of rodents (<xref class="xref-bibr" href="#ref-4" rid="xref-ref-4-1">Kennedy et al., 2004</xref>), alterations to antibody synthesis in humans may suggest that a PPAR-&#945;&#8211;independent mechanism influences PFAA immunotoxicity.<CoreSc1 atype="GSC" type="Con" conceptID="Con8" novelty="None" advantage="None"/></s>
      </p>
    </SEC>
    <SEC>
      <TITLE>FUNDING</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-33">
        <s sid="137">University of North Carolina, U.S. Environmental Protection Agency Cooperative Training Agreement (CT829472) partially supported J. DeWitt.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>Acknowledgments</TITLE>
      <p xmlns:xhtml="http://www.w3.org/1999/xhtml" id="p-34">
        <s sid="138">We thank D. Andrews and W. Williams for technical assistance.</s>
        <s sid="139">We thank Dr Jennifer Keller and Dr MaryJane Selgrade for reviewing the manuscript and providing helpful suggestions.</s>
      </p>
    </SEC>
    <SEC>
      <TITLE>References</TITLE>
    </SEC>
  </BODY>
</PAPER>